Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. reports insider share holdings for Executive Vice President Kevin Esch. As of the reporting date, he directly owns 267 shares of Zoetis common stock and indirectly holds 122.9323 common stock equivalents through the Zoetis Savings Plan, a 401(k) plan, as of December 31, 2025.
He also holds several equity awards: 772.2513, 306.1133, 86.8836 and 50.5137 restricted stock units that generally vest in thirds over three years from grant dates in 2023–2025, plus stock options on 1,181, 490, 545 and 391 shares at exercise prices of $156.64, $196.14, $162.07 and $201.3, typically vesting over three years and expiring ten years from grant. In addition, he holds 176.3958 phantom stock units under a supplemental savings plan that are settled in cash after separation from service.
The Vanguard Group has disclosed a significant ownership stake in Zoetis Inc. Vanguard reports beneficial ownership of 47,778,909 shares of Zoetis common stock, representing 10.84% of the outstanding class as of the reported date. Vanguard has no sole voting power over these shares but shares voting power over 2,768,187 shares. It reports sole dispositive power, meaning the ability to decide when to sell, over 43,395,509 shares and shared dispositive power over 4,383,400 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Zoetis.
Zoetis Inc. completed a private offering of $2.0 billion of 0.25% Convertible Senior Notes due 2029. The notes are senior unsecured, pay interest semiannually and are convertible into cash and, at Zoetis’ election, cash, shares or a combination based on an initial conversion rate of 6.7476 shares per $1,000 principal amount, equal to an initial conversion price of about $148.20 per share, a 22.5% premium to the last reported share price on December 15, 2025.
Zoetis expects net proceeds of about $1,969.6 million, allocating approximately $186.6 million to capped call transactions, about $248.0 million to repurchase roughly 2.1 million shares in concurrent private transactions, and about $1,535.0 million for additional share repurchases under its existing $6 billion authorization, which it expects to complete by no later than the first quarter of 2026.
The capped call agreements cover about 13.5 million shares, with strike and cap prices tied to the notes’ conversion economics, and are expected generally to reduce potential dilution or offset cash payments above principal if the notes are converted. Zoetis also obtained a waiver under its revolving credit facility that explicitly permits early conversions of the notes pursuant to their terms.
Zoetis Inc. announced a cash dividend for its common shareholders. The company declared a dividend of $0.53 per share for the first quarter of 2026. This dividend will be paid on March 3, 2026 to shareholders who are on record as owning Zoetis common stock at the close of business on January 20, 2026. The announcement was furnished as a Regulation FD disclosure, meaning it is intended to provide broad, fair access to this information for all investors.
Zoetis Inc. director reports no share ownership in initial filing. A director of Zoetis Inc. (ZTS) filed an initial beneficial ownership statement on Form 3, indicating that they currently hold no non-derivative Zoetis securities, with Table I showing "No securities beneficially held" and an amount of 0. The filing also shows no derivative securities such as options or warrants listed in Table II. The form is filed by a single reporting person and is signed by an attorney-in-fact on their behalf.
Zoetis Inc. disclosed a Form 4 reporting an equity award to one of its directors. On 12/01/2025, the director received 1,964 restricted stock units (RSUs) under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan at an exercise price of $127.25 per unit.
Each RSU represents a contingent right to receive one share of Zoetis common stock. The RSUs are scheduled to vest and be settled in Zoetis common shares on the first anniversary of the grant date, December 1, 2025, provided the director continues to serve through that date, with potential earlier vesting upon certain specified events.
Zoetis Inc. announced that it will host an Innovation Webcast at 8:30 a.m. ET on December 2, 2025. The webcast will feature a company presentation focused on its innovation-related topics in animal health. The presentation materials for this event are provided as an exhibit to the report, giving investors and stakeholders access to the same information shared during the webcast.
Zoetis Inc. filed its Q3 2025 report, showing steady growth. Revenue was $2.4 billion versus $2.388 billion a year ago, and diluted EPS reached $1.63 compared with $1.50. Net income attributable to Zoetis rose to $721 million from $682 million as cost of sales declined and operating expenses remained well managed. For the first nine months, revenue was $7,080 million versus $6,939 million, with diluted EPS of $4.65 versus $4.18.
Companion animal products continued to lead, with Q3 category revenue of $1,652 million, while livestock was $725 million. By product, parasiticides ($564 million), vaccines ($496 million), and dermatology ($472 million) were top contributors. Cash and cash equivalents were $2,084 million, and long-term debt (net) was $7,069 million after issuing $1.85 billion of new senior notes to redeem 2025 maturities. The company repurchased $381 million of shares in Q3 and $1,169 million year to date. The effective tax rate improved to 18.7% from 20.8%.
Zoetis Inc. (ZTS) furnished an update on its business by reporting third-quarter 2025 results and full-year 2025 guidance. The company announced these details in a press release dated November 4, 2025, which is provided as Exhibit 99.1.
The disclosure is presented under Item 2.02: Results of Operations and Financial Condition and is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not incorporated by reference unless specifically stated. The filing confirms Zoetis’ common stock trades on the NYSE under the symbol ZTS.
Zoetis (ZTS) appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025. The Board will increase from 12 to 13 members on that date.
The company states the appointment was not made pursuant to any third‑party arrangement and notes no related party transactions with Ms. Tilenius since the beginning of the last fiscal year. She will be eligible under Zoetis’ non‑employee director compensation program outlined in its 2025 proxy. Zoetis will enter into its standard indemnification agreement with her, and a press release announcing the appointment was issued on October 28, 2025.